Lv6
2938 积分 2022-07-12 加入
Target identification and assessment in the era of AI
19天前
已完结
Strategic adoption of model-informed drug development (MIDD) as an overarching business model in biotechnology and life science industry
23天前
已关闭
Racial/ethnic differences in survival and treatment response with PD-1/PD-L1 inhibitors in resectable non-small cell lung cancer: a meta-analysis of randomized controlled trials
1个月前
已完结
TMDD Modeling for Antibodies Directed Against Soluble Targets: Parameter Values for De Novo Modeling and Simulation From Experimental Data
1个月前
已完结
Learnings from Approved Antibody‐Drug Conjugates: Clinical Pharmacology Perspectives
1个月前
已完结
Strategy for streamlining antibody–drug conjugate pharmacokinetic assays
1个月前
已完结
On the coupling between a basic FcRn mechanism and target-mediated disposition of antibodies
1个月前
已完结
Lessons learned from QT prolongation risk assessment for antibody-drug conjugates in oncology
2个月前
已完结
QT Prolongation Risk of Antibody–Drug Conjugates
2个月前
已完结
Clinical Pharmacology Considerations in Antibody-Drug Conjugates Development
3个月前
已关闭
皖公网安备34019202002308
